4 unchanged sentences
The Company asserts infringement of the following eleven patents, which are listed in the FDA’s Orange Book for Arcutis’ ZORYVE ® 0.3% cream:
−Removed: 11,793,796;11,819,496;
and 12,016,848 (collectively, Asserted Patents).
−Removed: Arcutis seeks a judgment that Padagis has infringed or will infringe one or more claims of each of the Asserted Patents and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Padagis’s proposed generic product before expiration of each of the Asserted Patents found to infringe.
+Added: Arcutis seeks a judgment that Padagis has infringed or will infringe one or more claims of each of the Asserted Patents and based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Padagis’s proposed generic product before expiration of each of the Asserted Patents found to be infringed.
In March 2025, Arcutis agreed to file a joint stipulation to stay the ongoing patent litigation with Padagis at the request of Padagi s.
2 unchanged sentences
The 30-month stay will be extended for each day the stay is in place, starting March 24, 2025, until the stay is lifted.
−Removed: Teva Pharmaceutical Industries Ltd.
−Removed: filed Oppositions with the European Patent Office against two of our European patents, European Patent Nos.
−Removed: EP 3634380 B1 and EP 3684334 B1, on September 20, 2024 and August 13, 2024, respectively.
−Removed: These patents relate to topical roflumilast compositions.
−Removed: Oral proceedings concerning the oppositions to European Patent Nos.
−Removed: EP 3634380 B1 and EP 3684334 B1 have been scheduled for January 8, 2026, and December 4, 2025, respectively.
We may from time to time be involved in various legal proceedings of a character normally incident to the ordinary course of our business.
−Removed: We are not currently a defendant to any material litigation or other material legal proceedings.
+Added: We are not currently a defendant in any material litigation or other material legal proceedings.
+Added: For a discussion of our potential risks and uncertainties, see the information in Part I, "Part I, Item 1A.
+Added: Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025.
+Added: There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.
+Added: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
+Added: Issuer Purchases of Equity Securities
+Added: DEFAULTS UPON SENIOR SECURITIES
+Added: MINE SAFETY DISCLOSURES
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.